Genomics and synthetic biology are reshaping healthcare, with growing demand for precision medicine spotlighting stocks like PACB, MYGN and TWST.
Earlier in May 2026, Beam Therapeutics presented updated Phase 1/2 BEAM-302 data in alpha-1 antitrypsin deficiency, including detailed safety, durability and human neutrophil elastase findings, and co
Are there significant gains ahead for one (or both) of these innovative biotechs?
Beam Therapeutics (NASDAQ:BEAM) Chief Executive Officer John Evans said the company is advancing its base-editing platform across hematology and liver disease programs, with a potential biologics lice
Beam Therapeutics Inc (NASDAQ:BEAM) is one of the best gene therapy stocks to buy in 2026. The stock is up roughly 27% in the past six months and soared more than 60% in the past year. The Street expe
NTLA advances late-stage studies for nex-z and starts FDA filing for lonvo-z, positioning its pipeline for potential long-term growth.
Beam Therapeutics (NasdaqGS:BEAM) reported positive Phase 1/2 data for its BEAM-302 program at a major international conference. The gene editing therapy showed durable restoration of alpha-1 antitryp
Beam Therapeutics develops precision genetic medicines using base editing technology to target serious inherited diseases.
View interactive chart, options flow, and AI analysis for BEAM on Zorveq Finance.
Open BEAM Chart & Analysis →